Back

Effect of dapagliflozin in patients in Asia with heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER

27 August 2023 (09:24 - 09:42)
Organised by: Logo
Congress Presentation Part of: State-of-the art treatment of HFmrEF and HFpEF in 2023 Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Xiaowen Wang

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

3 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on treatment of HFmrEF and HFpEF in 2023: insights from RCTs
Professor L. Kober (Copenhagen, DK)
Slides Video
Presentation thumbnail
Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial
Doctor J. Butt (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Effect of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction treated with beta-blockers: the DELIVER trial
Doctor A. Peikert (Graz, AT)
Abstract Slides Video

Access the full session

Session thumbnail
State-of-the art treatment of HFmrEF and HFpEF in 2023
Video

The Event

Event poster

ESC Congress 2023

27 August 2023 09:24 CET
You may be interested in
thumbnail
Congress Session
State-of-the art treatment of HFmrEF and HFpEF in 2023
thumbnail
Congress Presentation
Effect of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction treated with beta-blockers: the DELIVER trial
thumbnail
Congress Presentation
Influence of background therapy on efficacy of dapagliflozin in patients with heart failure and improved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources